Maintenance strategies for relapse prevention and treatment

被引：0
作者：
Geramita, Emily [1 ]
Hou, Jing-Zhou [1 ]
Shlomchik, Warren D. [1 ]
Ito, Sawa [1 ]
机构：
[1] Univ Pittsburgh, Dept Med, Hematol & Oncol, Pittsburgh, PA USA
来源：
HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM | 2024年 / 01期
关键词：
STEM-CELL TRANSPLANTATION; ACUTE MYELOID-LEUKEMIA; DONOR LYMPHOCYTE INFUSION; REGULATORY T-CELLS; MISMATCHED HLA; AZACITIDINE; MULTICENTER; MDS; AML; REMISSIONS;
D O I：
10.1182/hematology.2024000589
中图分类号：
G40 [教育学];
学科分类号：
040101 ; 120403 ;
摘要：
Posttransplant relapse is the most signifcant challenge in allogeneic stem cell transplantation (alloSCT). Posttransplant interventions, in conjunction with optimal conditioning regimens and donor selection, are increasingly supported by evidence for their potential to prolong patient survival by promoting antileukemia or graft-versus-leukemia effects. Our review begins by highlighting the current evidence supporting maintenance therapy for relapse prevention in acute myeloid leukemia and acute lymphocytic leukemia. This includes a broad spectrum of strategies, such as targeted therapies, hypomethylating agents, venetoclax, and immunotherapies. We then shift our focus to the role of disease moni- toring after alloSCT, emphasizing the potential importance of early detection of measurable residual disease and a drop in donor chimerism. We also provide an overview of salvage therapies for overt relapse, including targeted therapies, chemotherapies, immunotherapies, donor lymphocyte infusion, and selected agents under investigation in ongoing clinical trials. Finally, we review the evidence for a second alloSCT (HSCT2) and discuss factors that impact donor selection for HSCT2.
引用
收藏
页码：635 / 643
页数：9
相关论文
共 71 条
  • [1] Horowitz M, Schreiber H, Elder A, Et al., Epidemiology and biology of relapse after stem cell transplantation, Bone Marrow Transpl, 53, 11, (2018)
  • [2] DeFilipp Z, Chen YB., How I treat with maintenance therapy after allogeneic HCT, Blood, 141, 1, (2023)
  • [3] Xuan L, Wang Y, Huang F, Et al., Sorafenib maintenance in patients with FLT3ITD acute myeloid leukaemia undergoing allogeneic haematopoietic stemcell transplantation: an openlabel, multicentre, randomised phase 3 trial, Lancet Oncol, 21, 9, (2020)
  • [4] Levis MJ, Hamadani M, Logan B, Et al., Gilteritinib as posttransplant maintenance for acute myeloid leukemia with internal tandem duplication mutation of FLT3, J Clin Oncol, 42, 15, (2024)
  • [5] Fathi AT, Kim HT, Soiffer RJ, Et al., Multicenter phase I trial of ivosidenib as maintenance treatment following allogeneic hematopoietic cell transplantation for IDH1mutated acute myeloid leukemia, Clin Cancer Res, 29, 11, (2023)
  • [6] Fathi AT, Kim HT, Soiffer RJ, Et al., Enasidenib as maintenance following allogeneic hematopoietic cell transplantation for IDH2mutated myeloid malignancies, Blood Adv, 6, 22, (2022)
  • [7] DeFilipp Z, Ancheta R, Liu Y, Et al., Maintenance tyrosine kinase inhibitors following allogeneic hematopoietic stem cell transplantation for chronic myelogenous leukemia: a Center for International Blood and Marrow Transplant Research Study, Biol Blood Marrow Transplant, 26, 3, (2020)
  • [8] Brissot E, Labopin M, Beckers MM, Et al., Tyrosine kinase inhibitors improve longterm outcome of allogeneic hematopoietic stem cell transplantation for adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia, Haematologica, 100, 3, (2015)
  • [9] Chen H, Xu LP, Zhang XH, Et al., Safety and outcomes of maintenance therapy with thirdgeneration tyrosine kinase inhibitor after allogeneic hematopoietic cell transplantation in Philadelphia chromosome positive acute lymphoblastic leukemia patients with T315I mutation, Leuk Res, 121, (2022)
  • [10] Pasvolsky O, Saliba RM, Popat UR, Et al., Azacitidine posttransplant maintenance improves disease progression in highrisk acute myeloid leukemia and myelodysplastic syndrome, Clin Lymphoma Myeloma Leuk, 24, 5, (2024)
12345678